VINCENT T. DEVITA, M.D.; RICHARD M. SIMON, Ph.D.; SUSAN M. HUBBARD, R.N., B.S.; ROBERT C. YOUNG, M.D.; COSTAN W. BERARD, M.D.; JOHN H. MOXLEY, M.D.; EMIL FREI, M.D.; PAUL P. CARBONE, M.D.; GEORGE P. CANELLOS, M.D.
ÃÂ¢ÃÂÃÂ¸Requests for reprints should be addressed to Vincent T. DeVita, Jr., M.D.; Room 3A52, Building 31, National Cancer Institute; Bethesda, MD 20205.
DEVITA VT, SIMON RM, HUBBARD SM, YOUNG RC, BERARD CW, MOXLEY JH, et al. Curability of Advanced Hodgkin's Disease with Chemotherapy: Long-Term Follow-up of MOPP-Treated Patients at the National Cancer Institute. Ann Intern Med. 1980;92:587-595. doi: 10.7326/0003-4819-92-5-587
Download citation file:
Published: Ann Intern Med. 1980;92(5):587-595.
The results of treatment of 198 patients with Hodgkin's disease with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were analyzed. Eighty percent attained complete remission, and 68% of patients achieving a complete remission have remained disease free beyond 10 years from the end of treatment. Results of autopsy on patients who died of other causes while in clinical complete remission did not show evidence of residual tumors except in one patient. Asymptomatic patients and patients with mixed-cellularity or lymphocytic-depleted Hodgkin's disease do significantly better than symptomatic patients and those with nodular sclerosing histologic type. Advanced Hodgkin's disease appears to be curable by chemotherapy.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only